WINKFEEL dextran videos and press

[Maeil Safety News / Reporter Lee Jeong-ja] A hands-on program for medical professionals sharing information about procedural techniques and product application for WINKFEEL Hera, a dextran-based vaginal filler, has concluded.

Practical training using WINKFEEL Hera took place at the autumn obstetrics and gynecology congress on October 18. The program expanded on vaginal filler applications and treatment topics discussed at EVE SYMPOSIUM 2026 in September, with a focus on practical techniques.

At the earlier symposium, medical professionals raised questions about product use and procedural methods. This autumn congress provided training allowing participants to observe the procedure directly.

Dr. Kim Ji-yeon of Y Queen Obstetrics and Gynecology performed the procedural demonstration. She then held a Q&A session with attending medical professionals, sharing information about procedural considerations and product-use methods.

WINKFEEL Hera, used in the training, is a medical device for tissue repair made primarily from cross-linked dextran. Its Ministry of Food and Drug Safety authorization number is Jeheo 13-1648.

저작권자ⓒ 매일안전신문. 무단전재-재배포 금지

A WINKFEEL Hera hands-on program for medical professionals took place at the 22nd Autumn Congress of the Korean Association of Obstetricians and Gynecologists (direct election system), held at Swiss Grand Hotel in Seoul on October 18, 2026.

According to WINKFEEL, Dr. Kim Ji-yeon of Y Queen Obstetrics and Gynecology led the demonstration, sharing the product-use process and considerations with participants.

The demonstration was followed by questions and answers about clinical application and the treatment process.

WINKFEEL Hera, used in the training, is a medical device for tissue repair made primarily from cross-linked dextran.

Reporter Kim Min-young

Copyright 비건뉴스. All rights reserved.

ABC News / Reporter Kim Su-chan — WINKFEEL Hera, a dextran-based vaginal filler, demonstrated an actual treatment procedure in an academic program for obstetricians and gynecologists and shared information on its clinical application.

At the autumn obstetrics and gynecology congress held on October 18, a hands-on program featured Dr. Kim Ji-yeon of Y Queen Obstetrics and Gynecology demonstrating a vaginal filler procedure using WINKFEEL Hera.

Dr. Kim introduced the procedure using the product and answered questions from attending medical professionals about its application in clinical practice and procedural techniques. The demonstration was followed by a Q&A session on product use and the treatment process.

WINKFEEL also attracted medical professionals’ interest in vaginal filler techniques and clinical application at EVE SYMPOSIUM 2026, held in September. This congress went beyond a lecture-centered format, providing an opportunity to share specific techniques through a live procedural demonstration and Q&A.

WINKFEEL Hera is a medical device for tissue repair whose principal material is cross-linked dextran particles. According to manufacturing authorization documents, it is designed to temporarily improve symptoms associated with vaginal laxity by injecting a gel containing dextran particles into the submucosal layer of the vaginal wall to add volume and thicken the wall.

Its Ministry of Food and Drug Safety authorization number is Jeheo 13-1648, and its official intended use is the “temporary improvement of symptoms caused by vaginal laxity in adult women.”

Dextran differs in physical properties from conventional hyaluronic acid fillers. While hyaluronic acid forms volume through its water-attracting properties, dextran is described as eliciting tissue responses associated with collagen formation around the injected particles.

According to educational materials for medical professionals, collagen formed around dextran particles may contribute to volume retention even as the particles biodegrade over time. However, the extent to which these characteristics affect actual treatment outcomes and duration requires clinical evaluation.

Clinical data relating to improvement in symptoms of vaginal laxity were also presented. A 24-week clinical trial using LiCOL GOLD, included under the same product authorization, involved 126 participants. In the primary efficacy assessment, 69.1% of the treatment group and 7.3% of the saline control group met the self-assessed vaginal laxity criterion at 24 weeks.

The hands-on session was significant in introducing the actual procedure to medical professionals based on WINKFEEL Hera’s authorized indications and clinical data, and in discussing its application in clinical practice.

Following the previous month’s symposium, the procedural demonstration program continued the exchange of information among medical professionals about the clinical use and procedural techniques of dextran-based vaginal fillers.

© ABC뉴스

Sponsorship of 'EVE SYMPOSIUM 2026', sharing product and treatment information that is easy for women to understand

DexWon (CEO Wonhaeng Lee) announced that it will begin providing information and marketing to general women with the first official symposium on the topic of WINKFEEL. The plan is to deliver accurate information about vaginal fillers to reduce anxiety caused by incorrect information and help women consult with medical staff while understanding the products and procedures.

'EVE SYMPOSIUM 2026' held at Andaz Seoul Gangnam on the 15th was hosted by S.THEPHARM and sponsored by DexWon. About 100 people, including 70 doctors, attended the event.

DexWon was in charge of marketing planning and practical work, including speaker consultation and content preparation, at this event. The company participated in designing how product information would be delivered and preparing content for communication with medical staff.

The area that DexWon will focus on in the future is providing product and treatment information that is easy for ordinary women to understand. The company plans to prepare content that explains the ingredients, purpose of use, and safety of vaginal fillers, and focus on accurately conveying the clinical experience of medical staff. Through this, the idea is to create an environment where women can comfortably ask questions and receive counseling.

WINKFEEL HERA is a medical device for tissue repair whose main ingredient is cross-linked dextran. It is used to temporarily improve symptoms caused by vaginal laxity by injecting into the submucosa of the female vaginal wall to fill the volume.

According to DexWon, even after the lecture that day, questions continued to be asked about vaginal filler treatment methods and clinical experience using WINKFEEL. The company plans to use the interests and questions of medical staff confirmed on site as a reference for future information provision and marketing content planning.

CEO Wonhaeng Lee is leading DexWon's business based on his experience participating in the launch and marketing of aesthetic medical products such as Derma Shine, Velast, and Rejuran before starting his business. DexWon is promoting the marketing of WINKFEEL by collaborating with Cheonghwa Medipower's research and development and manufacturing capabilities and S.THEPHARM's domestic sales and distribution network.

CEO Lee said, “WINKFEEL marketing has begun in earnest,” and added, “We will strive to increase understanding of vaginal fillers through accurate information and reduce anxiety caused by incorrect information.”

About 100 people, including 70 doctors, attended... After the lecture, questions related to the procedure continued / Demonstrated marketing planning and execution capabilities by directly conducting speaker consultations and content preparation

[mdtoday = Reporter Choi Min-seok] DexWon began full-scale academic marketing by carrying out marketing planning and practical work, including speaker consultation and content preparation, for the first official symposium on the topic of WINKFEEL.

‘EVE SYMPOSIUM 2026’ held at Andaz Seoul Gangnam on September 15th was hosted by S.THEPHARM and sponsored by DexWon. About 100 people, including 70 doctors, attended lectures and Q&A sessions about products and procedures.

According to DexWon, even after the lecture, questions continued to be asked about the vaginal filler procedure using WINKFEEL and improving urinary incontinence symptoms. Based on the lecture, the participating medical staff shared their opinions by asking questions about questions they had in actual treatment settings.

WINKFEEL HERA is a cross-linked dextran-based tissue repair medical device that is used to temporarily improve symptoms caused by vaginal laxity by filling the volume by injecting it into the submucosa of the vaginal wall. DexWon explains that the questions about procedures that came out at this event served as an opportunity to specify product and academic information needed by medical staff.

During the event preparation process, DexWon was responsible for negotiating speakers, preparing presentation-related content, and designing and executing marketing direction. The company plans to use content planning that connects the characteristics of the product and the interests of medical staff as its main competency, and use this symposium as the starting point for WINKFEEL marketing.

This direction reflects DexWon CEO Lee Won-haeng's experience in launching and marketing aesthetic medical products. Before starting his business, CEO Lee participated in the launch and marketing of Derma Shine, Velast, and Rejuran, and is applying that experience to WINKFEEL's product information delivery and market expansion.

The WINKFEEL business is promoted through a cooperative structure in which Cheonghwa Medipower is responsible for research and development and manufacturing, S.THEPHARM is responsible for domestic sales and distribution, and DexWon is responsible for marketing planning and execution. DexWon plans to focus on its role in connecting academic information for medical staff and explanatory content for general women.

In particular, the company plans to prepare content that conveys product ingredients, purpose of use, and safety-related information in an easy-to-understand manner targeting general women. The purpose is to reduce misinformation and anxiety about vaginal fillers and provide patients with the information they need to fully consult with medical staff.

CEO Lee evaluated that WINKFEEL marketing began in earnest with this symposium, and expressed his intention to strengthen the transfer of information between medical staff and patients based on product launch and marketing experience.

In addition to the WINKFEEL business, DexWon plans to expand its related business areas by preparing a skin booster containing dextran.

DexWon (CEO Wonhaeng Lee), a medical aesthetics distribution and marketing company, has begun entering the Japanese market with ‘WINKFEEL’, a cross-linked dextran-based medical device for tissue repair.

DexWon announced on the 12th that it has registered BBStem clinic Ginza (Director Byeon Hyun-seop) located in Ginza, Tokyo, Japan as WINKFEEL's first KOL (Key Opinion Leader) in Japan and is providing information about the product and dextran ingredients to local medical staff.

Director Byeon Hyun-seop is responsible for introducing WINKFEEL to Japanese medical staff and delivering information about the product and ingredients. Having previously introduced WINKFEEL to medical professionals in Japan, he plans to expand those contacts in cooperation with DexWon.

DexWon is currently focusing on increasing medical staff's understanding of the product and checking market response rather than expanding sales in Japan. The plan is to confirm the acceptability of the local market through sample evaluation and provision of information to medical staff.

Activities in the Japanese market also led to participation in academic conferences. DexWon participated in AMWC Japan 2026 (The Prince Park Tower Tokyo, Tokyo), an international aesthetic and anti-aging medical conference held on September 12-13, and introduced WINKFEEL.

In cooperation with HONMONO Co., Ltd., a Japanese distributor specializing in women’s health and vaginal fillers, DexWon operated an exhibition booth and conducted product consultations with Japanese medical staff and related industry officials.

According to the company, the medical staff who visited the site showed interest in the dextran ingredient, which was different from the material they were used to, and asked questions about the ingredient characteristics, product composition, and application method. DexWon provided product data and conducted sampling targeting medical staff and distribution personnel.

In the future, DexWon plans to gradually pursue cooperation with Japanese KOLs, medical staff training, sample evaluation, and establishment of a local distribution network.

CEO Lee Won-haeng said, "Japan is a market where medical staff and distributors introduce new ingredients and products after sufficient review. As we are currently in the early stages of promoting the product and confirming its marketability through sampling, we will expand the market by reflecting the opinions of local medical staff and distribution partners."

DexWon is in charge of WINKFEEL's domestic and overseas marketing and overseas export cooperation, and plans to expand the cooperation system linking KOLs and local distribution partners in each country with entry into the Japanese market.

[Rapportian] DexWon (CEO Wonhaeng Lee), a medical aesthetics distribution and marketing company, has begun local activities to enter the Japanese market for ‘WINKFEEL’, a cross-linked dextran-based tissue repair medical device.

DexWon announced on the 15th that it is in the process of registering BBStem clinic Ginza in Ginza, Tokyo, Japan as WINKFEEL's first KOL (Key Opinion Leader) in Japan. BBStem clinic Ginza director Byeon Hyun-seop is WINKFEEL's Japanese KOL and cooperates with DexWon and is responsible for delivering information about the product and dextran ingredients to local medical staff.

Director Byeon had previously introduced WINKFEEL to local medical staff in Japan. DexWon sees this first collaboration as a starting point for entering the Japanese medical market. However, the company explained that it is currently in the initial verification stage to increase the understanding of the product by medical staff and examine market reaction rather than expand sales.

DexWon plans to lay the foundation for entering the Japanese market by cooperating with local KOLs and participating in academic conferences, focusing on securing contacts with medical staff and evaluating products.

DexWon also participated in ‘AMWC Japan 2026’, an international beauty and anti-aging medical conference held at The Prince Park Tower Tokyo from September 12th to 13th. In collaboration with HONMONO Co., Ltd., a local Japanese distributor specializing in women’s health and vaginal fillers, the company is introducing WINKFEEL at its exhibition booth and conducting consultations with Japanese medical staff and related industry officials.

According to the company, Japanese medical staff who visited the booth showed interest in the dextran material, which is different from existing familiar ingredients, and asked questions about the characteristics of the ingredient, product composition, and actual application methods. DexWon is providing product data on site, conducting sampling with medical staff and distribution personnel, and examining the response of the Japanese market.

DexWon views participation in this conference as a process of expanding contact with local medical staff and forming an understanding of dextran-based products rather than short-term sales results. Considering the characteristics of the Japanese market, which requires sufficient review time to introduce new medical materials and products, the plan is to gradually promote KOL cooperation, medical staff training, sample evaluation, and establishment of a local distribution network.

Lee Won-haeng, CEO of DexWon, said, “Japan is a market where medical staff and distributors introduce new ingredients and products after thorough review, so the process of building trust is more important than short-term sales performance.” He added, “The KOL cooperation with BBStem clinic Ginza and the interest of medical staff confirmed at the AMWC Japan site are meaningful starting points for verifying the potential of WINKFEEL.”

“Currently, we are in the early stages of promoting the product through sampling and confirming its marketability,” he said. “By faithfully reflecting the opinions of Japanese KOLs and local professional distribution partners, we will build the market step by step to establish WINKFEEL as a brand trusted by Japanese medical staff.”

DexWon is in charge of WINKFEEL’s domestic and international marketing and overseas export cooperation. With this advance into Japan, the company plans to expand the cooperation system that connects KOLs in each country and local distribution partners, and raise the awareness of DexWon and WINKFEEL in the global medical aesthetics market through medical staff-centered academic and educational activities.